Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Cytokinetics reports strong Q1 2026 launch of MYQORZO with $4.8M sales and positive trial results for aficamten.
CYTK
$81.47
+$2.36 +2.98%

Cytokinetics reports strong Q1 2026 launch of MYQORZO with $4.8M sales and positive trial results for aficamten.

Company Fundamentals
05 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Cytokinetics launched MYQORZO (aficamten) in the U.S. in January 2026, achieving $4.8 million in net product revenue and strong early adoption by healthcare providers. The company announced positive Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), meeting key endpoints in symptom improvement and exercise performance. MYQORZO also received European Commission approval, with a planned launch in Germany in Q2 2026. Cytokinetics maintains its 2026 financial guidance despite a net loss of $206 million in Q1, driven by commercial launch costs and R&D expenses, while advancing multiple clinical trials globally.

More News (CYTK)

Cytokinetics grants stock options and RSUs to new employees as inducements under Nasdaq rules.

Cytokinetics grants stock options and RSUs to new employees as inducements under Nasdaq rules.

Cytokinetics granted stock options for 21,220 shares and 14,067 restricted stock units (RSUs) to 10 new employees hired in June and July 2026 as inducements to join the company. The RSUs vest over three years, while the stock options, priced at $82.6...

Company Fundamentals
Neutral
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App